| abstract |
The present invention relates to a new class of compounds, pharmaceutical compositions comprising such compounds, and diseases or disorders associated with abnormal or deregulated kinase activity, in particular Abl, BCR-Abl, PDGF-R, lck, SAPK2α. Use of such compounds for the treatment or prevention of diseases or disorders involving abnormal activation of p38, TGFβ, KDR, c-Kit, b-RAF, c-RAF, FLT1 and FLT4 kinase To do. |